In evaluating our proposal relative to recent literature [8], in particular, the study using radiolabeled AuNPs studded with substance P peptides for GBM treatment, it is clear that our approach offers several distinct advantages and complements existing strategies. The gene discussed is TAC1; the disease is glioblastoma.